AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.66
+0.07 (+1.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.59
Open6.59
Bid6.50 x 1400
Ask0.00 x 1800
Day's Range6.56 - 6.70
52 Week Range5.06 - 7.85
Volume315,853
Avg. Volume694,200
Market Cap616.967M
Beta (3Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.92
Trade prices are not sourced from all markets
  • Big Pharma faces the Senate in drug price hearings
    Yahoo Finance Video3 months ago

    Big Pharma faces the Senate in drug price hearings

    Yahoo Finance's Adam Shapiro, Julie Hyman, Jessica Smith, and Brian Sozzi discuss the Pharma executives testifying in the Senate drug price hearings.

  • Business Wire4 days ago

    Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT in New York, NY.

  • Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
    Zacks6 days ago

    Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss

    Aurinia (AUPH) delivered earnings and revenue surprises of 0.00% and 0.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press7 days ago

    Aurinia: 1Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 14 cents per share. Losses, adjusted for non-recurring gains, were 16 cents per share. The results matched Wall Street expectations. The ...

  • Business Wire7 days ago

    Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights

    - Conference call and webcast to be hosted today at 4:30pm EDT -

  • Business Wire11 days ago

    Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis

    In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. a late clinical-stage biopharmaceutical company with

  • Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks19 days ago

    Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire21 days ago

    Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s appointment is effective April 29, 2019 concurrent with the previously announced appointment of Mr. Peter Greenleaf as Chief Executive Officer and elevation of Dr. George Milne to Chairman of the Board. “On behalf of the entire organization, it is a pleasure to welcome Daniel onto Aurinia’s Board of Directors.

  • Business Wire27 days ago

    Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    Aurinia Pharmaceuticals Inc. today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co.

  • Former MedImmune president Greenleaf tapped to lead Canadian biotech
    American City Business Journals29 days ago

    Former MedImmune president Greenleaf tapped to lead Canadian biotech

    Peter Greenleaf was most recently CEO of Baltimore-based Cerecor Inc., a rare disease therapy company that topped the BBJ's list of fastest-growing public companies last year.

  • Business Wirelast month

    Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board

    Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors.

  • Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
    Zackslast month

    Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

  • Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript

    AUPH earnings call for the period ending December 31, 2018.

  • Associated Press2 months ago

    Aurinia: 4Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 17 cents per share. The biotechnology company posted revenue of $29,000 in the period, missing Street forecasts. Three analysts surveyed ...

  • Business Wire2 months ago

    Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

    Aurinia Pharmaceuticals Inc. today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S.

  • ACCESSWIRE2 months ago

    Aurinia Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 19, 2019 at ...

  • Business Wire2 months ago

    Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

    In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with The National Kidney Foundation (NKF), designed to raise awareness for kidney disease.

  • Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
    Zacks2 months ago

    Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

    Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

    Aurinia Pharmaceuticals Inc. today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes.

  • After Patent News, Aurinia Pharmaceuticals Still Has More to Prove
    InvestorPlace3 months ago

    After Patent News, Aurinia Pharmaceuticals Still Has More to Prove

    Aurinia Pharmaceuticals (NASDAQ:AUPH) leapt close to 20% on Monday. AUPH stock took off after the announcement of a new patent for the application method of its lupus nephritis drug.Source: Shutterstock This gave AUPH stock some much-needed excitement. Shares have languished between $5 and $6.50 for most of the past year, as investors await key clinical trial readouts. Bulls hope this patent news may finally break the gridlock and allow the stock to reach its highest levels in several years. However, Aurinia still has more work to do. Why The Patent News MattersThere was an interesting reaction with Aurinia stock after the news came out. At first, the stock didn't jump too much -- opening up just a few percent. But throughout the day, shares traded steadily higher as investors further considered the consequences.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Clinical-Stage Biotech Stocks to Buy On the one hand, this is an important development for Aurinia. One of the lingering issues with Aurinia has been that the primary patents around its Voclosporin were initially set to expire in 2022.Normally, a biotech company has a much longer window to generate exclusive revenues from its products before generic competitors launch their own versions. Given that short window, bears have suggested that Aurinia would have issues profiting adequately when the drug comes to market.Aurinia had several options to deal with this issue. They already managed to use one regulatory pathway to get a five-year extension out of 2027. So that had reduced the investment risk substantially. Still, most clinical stage biotech companies have patent exclusivity much longer than eight years, so investors were right to price that in as a risk for AUPH stock.With this patent, Aurinia may have overcome this challenge. What Changed, And What Hasn'tOn Monday, Aurinia published a press release, stating:"Notably, the allowed claims cover a method of modifying the dose of voclosporin in patients with lupus nephritis (LN) based on patient specific pharmacodynamic parameters."The new patent on Voclosporin runs out through 2037, giving Aurinia excellent protection from generic competition.That said, reading carefully, we see that the patent covers modification of the dose of Voclosporin, not the actual drug itself. It's seemingly unclear if generics could still compete with Voclosporin as long as they use a different dosing method. And there's still another much bigger question to deal with first: Will the drug be approved? After all, a patent won't matter if the drug never makes it to market.The all-important Phase III trial is set to deliver results around the end of 2019. It's far from a given that Voclosporin will succeed and go on to obtain FDA approval. The company's previous trial ran into significant safety issues with patients dying during the study. Given the FDA's concerns on safety issues, investors should be careful about assuming approval before the definitive trial results come in.On top of that, in the previous trial, the company's lower dose version of the drug showed a stronger clinical effect than the higher dose version. Again, there is a plausible explanation for this: management suggests the higher dose version wasn't tolerated well in patients. Still, an inconsistent dose response is another caution flag for biotech trials.To summarize, while the patent news is a plus for AUPH stock, don't overlook the small matter that the drug still has to perform in its pivotal phase III trial and pick up FDA approval. AUPH Stock VerdictThe company does have a few other options beyond the key lupus trial. It is also testing Voclosporin for other conditions, such as dry eye. That program produced a mixed set of clinical results recently. It missed its key endpoint, but showed stronger efficacy than expected.It's unclear what exactly this will mean for the dry eye program going forward. In any case, phase III results are still a few years away. Additionally, there is much more competition in that market than there would be for lupus nephritis.So, despite the flurry of attention for dry eye that Aurinia proponents have shown, don't get distracted from the main event. The lupus results should be coming up within a year from now. Those results will determine whether or not AUPH stock delivers for its shareholders.Finally, I should note the unambiguously positive thing about Aurinia at this point: its strong fiscal position. As of the most recent quarter, it had $139 million in cash, and was burning ~$45 million annually. That gives it more than two years to keep advancing the clinical pipeline. * 7 IPOs to Get Excited for in 2019 On top of that, the company subsequently announced a $30 million stock offering, which will add a few more quarters worth of working cash to its already substantial treasury. While Aurinia's ultimate success is far from certain, they've got a respected management team and enough cash to give Voclosporin time to attempt to prove its potential.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post After Patent News, Aurinia Pharmaceuticals Still Has More to Prove appeared first on InvestorPlace.

  • Business Wire3 months ago

    Aurinia Closes At-The-Market Facility

    Aurinia Pharmaceuticals Inc. today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market offerings of common shares in the capital of the Company, the Company has completed the sale of 4,608,409 common shares at a weighted average price of US$6.55 for aggregate gross proceeds of approximately US$30 million....

  • Here's Why Aurinia Pharmaceuticals' Stock Jumped Today
    Motley Fool3 months ago

    Here's Why Aurinia Pharmaceuticals' Stock Jumped Today

    It looks like an important patent that could protect its lead candidate is a done deal.

  • Business Wire3 months ago

    Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. The allowed claims broadly cover the novel voclosporin dosing protocol adhered to and required in both the previously reported Phase II AURA-LV study and the ongoing Phase III confirmatory AURORA study.

  • Business Wire3 months ago

    Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

    Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.